Oragenics (NYSEAMERICAN:OGEN – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.57) EPS for the quarter, FiscalAI reports.
Oragenics Price Performance
Shares of OGEN stock traded up $0.00 during trading hours on Friday, hitting $0.53. The stock had a trading volume of 6,801 shares, compared to its average volume of 23,474. Oragenics has a one year low of $0.48 and a one year high of $1.45. The stock’s 50-day moving average price is $0.56 and its two-hundred day moving average price is $0.64. The stock has a market capitalization of $2.40 million, a price-to-earnings ratio of -0.02 and a beta of 1.24.
Hedge Funds Weigh In On Oragenics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new position in Oragenics during the 4th quarter valued at approximately $26,000. Bank of America Corp DE raised its holdings in shares of Oragenics by 7,374.0% during the 2nd quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock worth $59,000 after acquiring an additional 15,338 shares in the last quarter. Finally, DRW Securities LLC raised its holdings in shares of Oragenics by 82.4% during the 4th quarter. DRW Securities LLC now owns 112,709 shares of the company’s stock worth $88,000 after acquiring an additional 50,900 shares in the last quarter. 18.71% of the stock is owned by institutional investors.
Oragenics Company Profile
Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.
The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.
Read More
- Five stocks we like better than Oragenics
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
